Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Sells $2,562,274.00 in Stock

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) insider Mo Qatanani sold 68,510 shares of the business's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total transaction of $2,562,274.00. Following the sale, the insider now directly owns 111,084 shares in the company, valued at approximately $4,154,541.60. This trade represents a 38.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Scholar Rock Stock Down 3.7 %

Shares of Scholar Rock stock traded down $1.45 during trading on Friday, hitting $37.70. 717,240 shares of the stock traded hands, compared to its average volume of 757,555. The company has a fifty day moving average price of $41.81 and a two-hundred day moving average price of $28.37. Scholar Rock Holding Co. has a twelve month low of $6.76 and a twelve month high of $46.98. The stock has a market cap of $3.53 billion, a P/E ratio of -16.04 and a beta of 0.50. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88.

Institutional Investors Weigh In On Scholar Rock

Institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP lifted its position in shares of Scholar Rock by 16.2% in the third quarter. Wellington Management Group LLP now owns 199,777 shares of the company's stock worth $1,600,000 after buying an additional 27,801 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Scholar Rock by 9.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 502,793 shares of the company's stock worth $4,027,000 after purchasing an additional 42,139 shares during the last quarter. Barclays PLC boosted its position in Scholar Rock by 103.4% during the third quarter. Barclays PLC now owns 165,449 shares of the company's stock worth $1,324,000 after purchasing an additional 84,118 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Scholar Rock by 7.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 94,795 shares of the company's stock valued at $759,000 after purchasing an additional 6,269 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Scholar Rock by 8.5% in the third quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company's stock valued at $12,361,000 after purchasing an additional 120,489 shares during the period. Institutional investors and hedge funds own 91.08% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on SRRK. Truist Financial raised their price objective on Scholar Rock from $36.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, November 25th. HC Wainwright increased their price target on shares of Scholar Rock from $40.00 to $50.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. Finally, Wedbush reaffirmed an "outperform" rating and set a $47.00 price objective on shares of Scholar Rock in a research report on Wednesday, January 29th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $40.43.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.